Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Jasper Ridge Partners L.P.

Jasper Ridge Partners L.P. grew its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 103.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 64,169 shares of the company's stock after acquiring an additional 32,601 shares during the period. Jasper Ridge Partners L.P. owned 0.07% of Scholar Rock worth $2,773,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC increased its stake in shares of Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after purchasing an additional 269 shares in the last quarter. Global Retirement Partners LLC grew its holdings in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after purchasing an additional 766 shares in the last quarter. Nisa Investment Advisors LLC increased its position in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares during the last quarter. Amalgamated Bank raised its stake in Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after purchasing an additional 620 shares in the last quarter. Finally, KBC Group NV bought a new position in Scholar Rock during the fourth quarter valued at $131,000. Institutional investors own 91.08% of the company's stock.

Insider Transactions at Scholar Rock

In other news, CFO Edward H. Myles sold 7,809 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $287,605.47. Following the completion of the transaction, the chief financial officer now directly owns 140,740 shares of the company's stock, valued at approximately $5,183,454.20. The trade was a 5.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the transaction, the director now owns 30,319 shares in the company, valued at $1,043,579.98. This trade represents a 3.21% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 255,231 shares of company stock valued at $9,220,236. Company insiders own 13.30% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wedbush restated an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Scholar Rock has a consensus rating of "Buy" and an average price target of $42.67.

Scholar Rock Trading Down 0.1%

SRRK traded down $0.02 on Wednesday, reaching $31.38. 124,782 shares of the company traded hands, compared to its average volume of 1,264,826. The company has a market cap of $2.98 billion, a P/E ratio of -13.33 and a beta of 0.37. The firm has a fifty day simple moving average of $31.46 and a two-hundred day simple moving average of $35.91. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). As a group, equities research analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current year.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.